"Third-generation" Synergy and Cre8 DES show promiseTheHeart.OrgDr Ian Meredith (Monash Medical Center, Melbourne, Australia) presented results from the first-in-human EVOLVE trial, testing the everolimus-eluting Synergy stent (Boston Scienti…
Results of the TWENTE trial reported at TCT 2011Medical XpressThe TWENTE clinical trial, which compared two second generation drug-eluting stents – zotarolimus and everolimus-eluting stents – established non-inferiority between the two stents as me…
TCT: Non-inferiority trial shows Synergy DES deliversCardiovascular Business“The results really support the safety and efficacy of this novel bioabsorbable polymer Synergy everolimus-eluting stent for the treatment of patients with de novo coronary a…
Angioplasty.OrgZotarolimus stent matches everolimus DES in TWENTETheHeart.OrgSan Francisco, CA – Another randomized controlled "real-world" trial has demonstrated noninferiority of the Resolute zotarolimus-eluting stent (Medtronic) against th…
Results of the EVOLVE trial reported at TCT 2011PhysOrg.com"These results support the safety and efficacy of the novel abluminal bioabsorbable polymer everolimus-eluting stent for the treatment of patients with de novo coronary artery disease. Add…
Orphan drug status granted to sirolimusOSN SuperSiteThe US Food and Drug Administration granted orphan drug designation to sirolimus (DE-109) for the treatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, no…
Santen Sirolimus drug secures FDA orphan drug statusPharmaceutical Business ReviewThe US FDA has granted orphan drug status for Santen's sirolimus (DE-109, rapamycin) to treat chronic/refractory anterior non-infectious uveitis, non-infectious inter…
Veloxis Pharmaceuticals Presents LCP-Tacro™ Phase 3 Data at the American …Sacramento BeeLCP-Tacro™ enabled a reduction in dose of 20% through 12 months following a switch from Prograf® as measured by median tacrolimus dose (mg/kg/day) (p<0.00…
OSN SuperSitePulsed corticosteroid regimen reduces postoperative ocular inflammationOSN SuperSiteEric D. Donnenfeld, MD, OSN Cornea/External Disease Board Member and lead study author, attributed the safety and efficacy of difluprednate to a neuroprote…
Cyclosporine A 1% an alternative to corticosteroids for treating subepithelial …OSN SuperSiteA study found that cyclosporine A eye drops were successful in patients who could not be tapered from corticosteroid eye drops. Cyclosporine A 1% eye drops f…